These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8570515)

  • 21. Pharmacoeconomics and immunotherapy.
    Berto P
    Eur Ann Allergy Clin Immunol; 2007; 39 Spec No():12-6. PubMed ID: 18924461
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Value of Information in Asia: Concepts, Current Use, and Future Directions.
    Dilokthornsakul P; McQueen RB; Chaiyakunapruk N; Spackman E; Watanabe JH; Campbell JD
    Value Health Reg Issues; 2016 May; 9():99-104. PubMed ID: 27881269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Standardization of the economic evaluation of health technologies. European developments.
    Rovira J
    Med Care; 1996 Dec; 34(12 Suppl):DS182-8. PubMed ID: 8969325
    [No Abstract]   [Full Text] [Related]  

  • 24. Navigating joint HTA, procurement, and fair pricing: evidence-based insights and practical recommendations - A meeting report from ISPOR regional conference in Warsaw, 2019.
    Inotai A; Németh B
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):379-381. PubMed ID: 31159614
    [No Abstract]   [Full Text] [Related]  

  • 25. [Pharmacoeconomics in contemporary medicine].
    Czech M
    Pol Merkur Lekarski; 2004 May; 16 Suppl 1():16-9. PubMed ID: 15524007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacoeconomics in the new millennium. A pharmaceutical industry perspective.
    Thwaites R; Townsend RJ
    Pharmacoeconomics; 1998 Feb; 13(2):175-80. PubMed ID: 10178645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacoeconomics comes of age?
    Walley T; Breckenridge A
    Clin Pharmacol Ther; 2008 Aug; 84(2):279-80. PubMed ID: 18563057
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparing Use of Health Technology Assessment in Pharmaceutical Policy among Earlier and More Recent Adopters in the European Union.
    Beletsi A; Koutrafouri V; Karampli E; Pavi E
    Value Health Reg Issues; 2018 Sep; 16():81-91. PubMed ID: 30316029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmacoeconomics. I].
    Kolár J
    Ceska Slov Farm; 1997 Feb; 46(1):9-13. PubMed ID: 9221090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The value of innovation in decision-making in health care in Central Eastern Europe - The Sixth International Conference, 2 June 2017, Belgrade, Serbia.
    Novakovic T; Martin AP; Parker M; Ferrario A; Vukovic S; Łanda K; Duba J; Dankó D; Kotsopoulos N; Godman B; Ristic J; Stefanovic D; Tesic D
    Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):519-521. PubMed ID: 28946800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expert review of pharmacoeconomics and outcomes research: high impact articles from 2023.
    Hiligsmann M; DeKoven MP; Doshi R; Gotay C; Lazzaro C; Sankaranarayanan J; Hajjar R
    Expert Rev Pharmacoecon Outcomes Res; 2024 Jun; 24(5):577-579. PubMed ID: 38591254
    [No Abstract]   [Full Text] [Related]  

  • 33. Emerging role of pharmacoeconomics in the research and development decision-making process.
    DiMasi JA; Caglarcan E; Wood-Armany M
    Pharmacoeconomics; 2001; 19(7):753-66. PubMed ID: 11548911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Social and ethical analysis in health technology assessment.
    Tantivess S
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S81-6. PubMed ID: 24964703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacoeconomics: state of the art in 1997.
    Schulman KA; Linas BP
    Annu Rev Public Health; 1997; 18():529-48. PubMed ID: 9143730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Verification of Decision-Analytic Models for Health Economic Evaluations: An Overview.
    Dasbach EJ; Elbasha EH
    Pharmacoeconomics; 2017 Jul; 35(7):673-683. PubMed ID: 28456972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of economic models in randomized clinical trials.
    Hlatky MA
    Am Heart J; 1999 May; 137(5):S41-6. PubMed ID: 10220595
    [No Abstract]   [Full Text] [Related]  

  • 38. International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework.
    Malone DC; Berg NS; Claxton K; Garrison LP; IJzerman M; Marsh K; Neumann PJ; Sculpher M; Towse A; Uyl-de Groot C; Weinstein MC
    J Clin Oncol; 2016 Aug; 34(24):2936-7. PubMed ID: 27298420
    [No Abstract]   [Full Text] [Related]  

  • 39. [Practice of pharmaceutical care--therapeutic drug monitoring and pharmacoeconomics of glaucoma--].
    Ikeda H
    Yakugaku Zasshi; 2007 Sep; 127(9):1441-8. PubMed ID: 17827924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic applications and pharmacoeconomics of microneedle technology.
    Richter-Johnson J; Kumar P; Choonara YE; du Toit LC; Pillay V
    Expert Rev Pharmacoecon Outcomes Res; 2018 Aug; 18(4):359-369. PubMed ID: 29889571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.